MK-0616: First Oral PCSK9 Inhibitor Achieves 60% LDL Reduction in Phase 3, Could Replace Injections

What Is MK-0616 and How Does an Oral PCSK9 Inhibitor Work?

MK-0616, developed by Merck, is a first-in-class oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a serine protease produced primarily by the liver that binds to LDL receptors (LDLR) on hepatocyte surfaces, promoting their internalization and lysosomal degradation. By reducing the number of LDL receptors available to clear LDL particles from the circulation, PCSK9 effectively raises blood LDL cholesterol levels. Inhibiting PCSK9 preserves LDL receptor recycling, increasing the liver's capacity to remove LDL from the bloodstream.

The existing PCSK9 inhibitors — evolocumab (Repatha) and alirocumab (Praluent) — are fully human monoclonal antibodies requiring subcutaneous injection every 2–4 weeks. While highly effective, their injectable route has limited real-world uptake: studies suggest fewer than 5% of eligible patients in the United States receive PCSK9 inhibitor therapy despite established cardiovascular outcome benefits demonstrated in the FOURIER and ODYSSEY OUTCOMES trials. MK-0616 overcomes this barrier through its unique macrocyclic peptide scaffold, which is orally bioavailable thanks to its cyclic structure that resists gastrointestinal proteolysis and a permeation enhancer that facilitates intestinal absorption. The drug is taken as a single daily pill with water and achieves steady-state PCSK9 inhibition within the first weeks of initiation.

How Effective Is MK-0616 at Lowering LDL Cholesterol?

Phase 3 trials of MK-0616 enrolled patients with established ASCVD (prior myocardial infarction, stroke, or peripheral artery disease) or heterozygous familial hypercholesterolemia (HeFH) who had LDL-C ≥ 70 mg/dL despite maximally tolerated statin therapy with or without ezetimibe. These randomized, placebo-controlled studies evaluated multiple doses of MK-0616 taken once daily.

The 30mg dose achieved an LDL-C reduction of approximately 60% from baseline, consistent with results from the Phase 2b trial that demonstrated similar magnitude of LDL lowering. MK-0616 also substantially reduced non-HDL cholesterol (approximately 50%), apolipoprotein B (approximately 50%), and lipoprotein(a) (approximately 25%). The majority of patients on the 30mg dose achieved LDL-C levels below the guideline-recommended targets for very high-risk ASCVD patients. These results are comparable to injectable evolocumab 140mg biweekly (which typically achieves 58–62% LDL reduction in statin-treated patients) and alirocumab 150mg biweekly (54–63% LDL reduction), as established in the FOURIER and ODYSSEY OUTCOMES programs.

A large cardiovascular outcomes trial (CVOT) is underway to determine whether MK-0616's LDL-lowering translates into reductions in major adverse cardiovascular events (MACE). Based on the consistent relationship between LDL reduction and cardiovascular risk established by the Cholesterol Treatment Trialists' Collaboration meta-analyses — approximately 22% relative risk reduction per 1 mmol/L LDL lowering — the anticipated 60% LDL reduction with MK-0616 would be expected to yield a meaningful reduction in cardiovascular events.

What Are the Side Effects of MK-0616?

The safety and tolerability profile of MK-0616 across clinical trials has been favorable, with overall adverse event rates comparable between drug and placebo groups. The most commonly reported adverse events included upper respiratory tract infection, headache, and mild gastrointestinal symptoms such as diarrhea and nausea, all occurring at rates similar to placebo. Serious adverse events and treatment discontinuation due to adverse events were low and not significantly different from placebo.

Notably, MK-0616 does not cause the injection-site reactions (erythema, pain, pruritus) that affect an estimated 5–10% of patients on injectable PCSK9 inhibitors and contribute to treatment discontinuation. Liver function tests and renal function have remained stable in trials. There were no signals of neurocognitive adverse events — a concern that was thoroughly evaluated in the EBBINGHAUS substudy of the FOURIER trial and found to be unrelated to PCSK9 inhibition or very low LDL-C levels. Drug-drug interaction studies have confirmed no clinically significant interactions with statins, ezetimibe, or common cardiovascular medications. The favorable tolerability profile, combined with the convenience of once-daily oral dosing, supports MK-0616's potential to dramatically increase PCSK9 inhibitor utilization among eligible patients.

Could MK-0616 Replace Injectable PCSK9 Inhibitors?

The potential of MK-0616 to transform lipid-lowering therapy rests on its ability to deliver PCSK9 inhibition — previously available only via injection — in a simple daily pill. The barriers to injectable PCSK9 inhibitor adoption have been well documented: injection aversion, self-administration difficulty (particularly in elderly patients), cold-chain storage requirements, prior authorization burden, and high out-of-pocket costs. Despite the proven cardiovascular benefits of PCSK9 inhibition in FOURIER (evolocumab: 15% relative reduction in MACE) and ODYSSEY OUTCOMES (alirocumab: 15% MACE reduction), real-world utilization remains low among eligible patients.

MK-0616 addresses the administration barrier directly. If the ongoing CVOT confirms cardiovascular event reduction consistent with the degree of LDL lowering, MK-0616 could become a first-line add-on therapy for patients not at LDL goal on statins. The drug's potential market is substantial: millions of adults in the United States have ASCVD or HeFH with LDL-C above target despite statin therapy. The combination of demonstrated LDL-lowering efficacy, favorable tolerability, and oral convenience positions MK-0616 as a potential landmark advance in cardiovascular pharmacology. Merck has been advancing regulatory submissions, with potential FDA approval anticipated in the coming years.